Brief: Abbisko Cayman Says Abbisko Therapeutics Receives $85Mn From Merck
29/05/2025 09:17
May 29 (Reuters) - Abbisko Cayman Ltd 2256.HK: ABBISKO THERAPEUTICS RECEIVES US$85MN FROM- MERCK IN CONSIDERATION FOR PIMICOTINIB (ABSK021) GLOBAL- COMMERCIALIZATION OPTION Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration